Pixium Vision SA
LSE:0QVB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pixium Vision SA
LSE:0QVB
|
FR |
|
S
|
Shanghai Smart Control Co Ltd
SZSE:001266
|
CN |
|
B
|
Bombay Oxygen Investments Ltd
BSE:509470
|
IN |
|
LX Semicon Co Ltd
KRX:108320
|
KR |
|
B
|
Baroque Japan Ltd
TSE:3548
|
JP |
|
New World Department Store China Ltd
HKEX:825
|
HK |
|
Singular People SA
MAD:SNG
|
ES |
|
E
|
Erytech Pharma SA
PAR:ERYP
|
FR |
|
Frenkel Topping Group PLC
LSE:FEN
|
UK |
|
West Coast Paper Mills Ltd
NSE:WSTCSTPAPR
|
IN |
|
K
|
Kelington Group Bhd
KLSE:KGB
|
MY |
|
Deutsche Post AG
OTC:DHLGY
|
DE |
|
Algonquin Power & Utilities Corp
TSX:AQN
|
CA |
|
I
|
Innospec Inc
LSE:0JAX
|
US |
|
B
|
British American Tobacco PLC
NYSE:BTI
|
UK |
|
Hindalco Industries Ltd
NSE:HINDALCO
|
IN |
|
L
|
Logory Logistics Technology Co Ltd
HKEX:2482
|
CN |
|
KEI Industries Ltd
NSE:KEI
|
IN |
Pixium Vision SA
Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
